{"id":"https://openalex.org/W3146729261","doi":"https://doi.org/10.1145/3446569.3446577","title":"Analysis on the Financial Performance Impact of Chinese Pharmaceutical Companies' Cross-border M&A","display_name":"Analysis on the Financial Performance Impact of Chinese Pharmaceutical Companies' Cross-border M&A","publication_year":2020,"publication_date":"2020-12-18","ids":{"openalex":"https://openalex.org/W3146729261","doi":"https://doi.org/10.1145/3446569.3446577","mag":"3146729261"},"language":"en","primary_location":{"id":"doi:10.1145/3446569.3446577","is_oa":false,"landing_page_url":"https://doi.org/10.1145/3446569.3446577","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"2020 The 4th International Conference on Software and e-Business","raw_type":"proceedings-article"},"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5047278567","display_name":"Boge Wang","orcid":null},"institutions":[{"id":"https://openalex.org/I49185572","display_name":"Yunnan University of Finance And Economics","ror":"https://ror.org/04rhev598","country_code":"CN","type":"education","lineage":["https://openalex.org/I49185572"]}],"countries":["CN"],"is_corresponding":true,"raw_author_name":"Boge Wang","raw_affiliation_strings":["Yunnan University of Finance and Economics, China"],"affiliations":[{"raw_affiliation_string":"Yunnan University of Finance and Economics, China","institution_ids":["https://openalex.org/I49185572"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5047278567"],"corresponding_institution_ids":["https://openalex.org/I49185572"],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.29557353,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"30","issue":null,"first_page":"94","last_page":"98"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12851","display_name":"Firm Innovation and Growth","score":0.34850001335144043,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T12851","display_name":"Firm Innovation and Growth","score":0.34850001335144043,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T12722","display_name":"Innovation Policy and R&D","score":0.34769999980926514,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10019","display_name":"Corporate Finance and Governance","score":0.32179999351501465,"subfield":{"id":"https://openalex.org/subfields/1402","display_name":"Accounting"},"field":{"id":"https://openalex.org/fields/14","display_name":"Business, Management and Accounting"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/mergers-and-acquisitions","display_name":"Mergers and acquisitions","score":0.8075166940689087},{"id":"https://openalex.org/keywords/china","display_name":"China","score":0.7513642311096191},{"id":"https://openalex.org/keywords/business","display_name":"Business","score":0.7299585342407227},{"id":"https://openalex.org/keywords/pharmaceutical-industry","display_name":"Pharmaceutical industry","score":0.5902377367019653},{"id":"https://openalex.org/keywords/finance","display_name":"Finance","score":0.46247637271881104},{"id":"https://openalex.org/keywords/scale","display_name":"Scale (ratio)","score":0.43893855810165405},{"id":"https://openalex.org/keywords/industrial-organization","display_name":"Industrial organization","score":0.4214808940887451},{"id":"https://openalex.org/keywords/accounting","display_name":"Accounting","score":0.36986103653907776}],"concepts":[{"id":"https://openalex.org/C548217281","wikidata":"https://www.wikidata.org/wiki/Q731112","display_name":"Mergers and acquisitions","level":2,"score":0.8075166940689087},{"id":"https://openalex.org/C191935318","wikidata":"https://www.wikidata.org/wiki/Q148","display_name":"China","level":2,"score":0.7513642311096191},{"id":"https://openalex.org/C144133560","wikidata":"https://www.wikidata.org/wiki/Q4830453","display_name":"Business","level":0,"score":0.7299585342407227},{"id":"https://openalex.org/C2779652045","wikidata":"https://www.wikidata.org/wiki/Q507443","display_name":"Pharmaceutical industry","level":2,"score":0.5902377367019653},{"id":"https://openalex.org/C10138342","wikidata":"https://www.wikidata.org/wiki/Q43015","display_name":"Finance","level":1,"score":0.46247637271881104},{"id":"https://openalex.org/C2778755073","wikidata":"https://www.wikidata.org/wiki/Q10858537","display_name":"Scale (ratio)","level":2,"score":0.43893855810165405},{"id":"https://openalex.org/C40700","wikidata":"https://www.wikidata.org/wiki/Q1411783","display_name":"Industrial organization","level":1,"score":0.4214808940887451},{"id":"https://openalex.org/C121955636","wikidata":"https://www.wikidata.org/wiki/Q4116214","display_name":"Accounting","level":1,"score":0.36986103653907776},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.0},{"id":"https://openalex.org/C199539241","wikidata":"https://www.wikidata.org/wiki/Q7748","display_name":"Law","level":1,"score":0.0},{"id":"https://openalex.org/C17744445","wikidata":"https://www.wikidata.org/wiki/Q36442","display_name":"Political science","level":0,"score":0.0},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.0},{"id":"https://openalex.org/C62520636","wikidata":"https://www.wikidata.org/wiki/Q944","display_name":"Quantum mechanics","level":1,"score":0.0},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1145/3446569.3446577","is_oa":false,"landing_page_url":"https://doi.org/10.1145/3446569.3446577","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"2020 The 4th International Conference on Software and e-Business","raw_type":"proceedings-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/9","score":0.46000000834465027,"display_name":"Industry, innovation and infrastructure"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1756400570","https://openalex.org/W1582861966","https://openalex.org/W1484992515","https://openalex.org/W612546726","https://openalex.org/W3176377222","https://openalex.org/W3107667671","https://openalex.org/W2371459757","https://openalex.org/W2097827202","https://openalex.org/W2520062152","https://openalex.org/W4386292311"],"abstract_inverted_index":{"With":[0],"the":[1,29,49,57,61,64,69,73,86,88,91,100,110],"development":[2],"of":[3,31,51,60,90],"China's":[4],"pharmaceutical":[5,10,15,38],"market,":[6],"more":[7,9],"and":[8,17,24,53,63,67,80,109],"companies":[11,18],"are":[12,123],"targeting":[13],"overseas":[14],"markets":[16],"to":[19],"conduct":[20],"large-scale":[21],"cross-border":[22],"mergers":[23,52],"acquisitions.":[25],"This":[26],"article":[27],"takes":[28],"acquisition":[30],"Gland":[32],"by":[33],"Fosun":[34,83],"Pharmaceuticals,":[35],"a":[36,46],"leading":[37],"company":[39,62],"in":[40,98],"China,":[41],"as":[42],"an":[43],"example,":[44],"conducts":[45],"research":[47],"on":[48,118],"motivations":[50],"acquisitions":[54],"from":[55],"both":[56],"internal":[58],"reasons":[59],"external":[65],"environment,":[66],"analyzes":[68],"financial":[70,76,107],"performance":[71],"through":[72],"four":[74],"major":[75],"ratio":[77],"analysis":[78],"methods,":[79],"concludes":[81],"that":[82],"Pharma":[84],"After":[85],"merger,":[87],"purpose":[89],"merger":[92,101],"can":[93],"be":[94],"basically":[95],"achieved,":[96],"but":[97],"general,":[99],"has":[102,113],"not":[103,114],"significantly":[104],"improved":[105],"its":[106],"performance,":[108],"synergistic":[111],"effect":[112],"fully":[115],"appeared.":[116],"Based":[117],"this":[119],"conclusion,":[120],"relevant":[121],"suggestions":[122],"made.":[124]},"counts_by_year":[],"updated_date":"2025-11-06T03:46:38.306776","created_date":"2025-10-10T00:00:00"}